Third patient implanted with Ventracor device
23 October, 2003 by Melissa TrudingerVentracor (ASX: VCR) has implanted its "artificial heart" device into a third patient as part of the pilot trial being conducted at the Alfred Hospital in Melbourne.
AtCor to enter US market
23 October, 2003 by Melissa TrudingerSydney-based devices company AtCor Medical is readying itself to make a major push into the US market with its range of cardiovascular diagnostic devices.
Virax wins US bioterrorism job
22 October, 2003 by Melissa TrudingerVirax (ASX:VHL) has received approval from the US State Department to participate in a collaboration to develop a modified smallpox vaccine.
Prima subsidiary claims arthritis treatment find
22 October, 2003 by Graeme O'NeillPrima BioMed (ASX:PRR) subsidiary Arthron believes it has found a new way of blocking the inflammatory reaction responsible for the crippling autoimmune disease rheumatoid arthritis.
Benitec claims 'multiple warhead' RNAi breakthrough
22 October, 2003 by Melissa TrudingerBenitec (ASX:BLT) has developed technology allowing simultaneous disabling of multiple genes through RNA interference.
Old fence to some, goldmine to BioProspect
21 October, 2003 by Graeme O'NeillAn ancient fence, its posts hewn from local trees, caught Matt Kealley's eye during a bioprospecting expedition in north Queensland's monsoonal woodlands a few years ago.
Visiomed receives TGA approval for MicroDERM Hair
21 October, 2003 by Melissa TrudingerPerth-based devices company Visiomed (ASX:VSG), formerly known as Xcell Diagnostics, has received TGA approval for a hair analysis system which uses the same computerised image analysis platform technology as its skin cancer diagnostic system.
AustCancer to launch new products in US market
20 October, 2003 by Melissa TrudingerAustralian Cancer Technology (ASX:ACU) has completed the acquisition of a range of nutraceuticals designed specifically for cancer patients undergoing treatment.
NZ biotech welcomes govt's GM decision
20 October, 2003 by Graeme O'NeillNew Zealand's biotechnology industry will emerge into the sunlight next week, after the NZ Parliament voted decisively to end the nation's moratorium on field trials of genetically modified organisms (GMOs).
Investment opportunities: The next big thing
17 October, 2003 by Melissa TrudingerMelissa Trudinger asks industry insiders where the next big investment opportunities will come from -- and identifies a few other likely chances.
Amrad unveils new CEO, chairman, business model
15 October, 2003 by Melissa TrudingerDr Peter Smith, a British-born former biotech analyst and company founder, has been named as the new CEO of Melbourne firm Amrad (ASX:AML) at its annual general meeting today.
New alliance gives GTG stronger grip on gene testing
15 October, 2003 by Graeme O'NeillGenetic Technologies (ASX:GTG) has formed a strategic alliance with the Perth-based CY O'Connor ERADE Village Foundation that is intended to strengthen GTG's already formidable -- and controversial -- grip on gene testing using non-coding DNA sequences.
Eiffel hires ex-PowderJect manager as COO
15 October, 2003 by Melissa TrudingerDrug reengineering company Eiffel Technologies has recruited former PowderJect technologies manager Dr Pascal Hickey as chief operating officer.
Bionomics files for new epilepsy patent
14 October, 2003 by Graeme O'NeillAdelaide biotech Bionomics (ASX:BNM, US OTC:BMICV)) has filed a provisional patent application on a DNA diagnostic test for a benign form of epilepsy that causes seizures in early childhood.
Polartechnics secures commitment to raise $5m
13 October, 2003 by Tanya HollisMedical device company Polartechnics (ASX:PLT) today announced it had secured commitments to raise $5 million to assist in international marketing of its three core products.
